Much like the early days of coronary stenting, percutaneous aortic valve replacement has captured the imagination of physicians and industry alike. Although many challenges remain, most physicians in the heart valve community appear optimistic that transcatheter aortic valve technologies will eventually achieve a prominent place in the treatment armamentarium, a development that would put these devices on track to achieve over $1 billion in sales within the next five years.
by Mary Thompson
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
